Cardiovascular Disease (CVD) and Mortality: Treatment Studies

September 21, 2007


GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and Vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 354:447-455, 1999.
Holub, D. J., and Holub, B. J. Omega-3 fatty acids from fish oils and cardiovascular disease. Molecular and Cellular Biochemistry. 263:217-225, 2004.
Krauss, R.M., et al. AHA Dietary Guidelines, Revision 2000: A statement for healthcare professionals from the nutrition committee of the American Heart Association. Circulation. 102: 2284-2299, 2000.
Studer, M., et al. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch. Intern. Med. 165: 725-30, 2005.


Recent studies have focused on the potential for fish oil supplements enriched with DHA/EPA to modify 'hard' clinical endpoints such as cardiac mortality in patients and at-risk subjects. The 1999 GISSI Prevenzione trial results from Italy indicated a highly beneficial effect of DHA/EPA supplementation in patients who had experienced a myocardial infarction. The overall findings on the effect of fish oil supplementation relative to controls on follow-up are outlined in Figure 1 below. The 11,324 patients who had experienced a myocardial infarction were assigned to supplemental interventions following the introduction of a Mediterranean-type diet (which included moderate fish consumption), as well as aggressive treatment with various pharmaceutical agents for cardiovascular care. Approximately half the patients received omega-3 supplementation providing 850-882 mg/day of DHA plus EPA (combined). Over the follow-up interval of 3.5 years, the individuals who received omega-3 supplementation were found to exhibit an approximate 30% reduction in overall cardiovascular deaths and a reduction in sudden cardiac death of about 45%.

Effect of omega-3 fish oil supplementation on death rates

Figure 1: Effect of omega-3 fish oil supplementation on death rates.

Studer et al. (2005) has recently compiled and published a systematic search of randomized controlled clinical trials on various lipid-lowering interventions. A summary of this search is depicted below in Figure 2. In the 33 trials where statin (cholesterol-lowering) medication was employed, an overall 22 percent reduction in cardiac mortality was realized. Interestingly, a 32% in cardiac mortality was observed overall in the 12 studies employing higher intakes of n-3 PUFA (omega-3 fatty acids). These and other findings have led the American Heart Association to officially recommend one fatty fish meal per day or alternatively omega-3 fatty acid intake as DHA/EPA (combined) of 900 mg/day - an amount shown to beneficially affect coronary heart disease mortality rates in patients with coronary disease.

Cardiac mortality in relation to different treatments

Figure 2: Cardiac mortality in relation to different treatments.

Return to Cardiovascular Health Research